Equities research analysts at StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a note issued to investors on Wednesday. The firm set a “sell” rating on the stock.
Navidea Biopharmaceuticals Price Performance
NAVB opened at $0.00 on Wednesday. The company has a market capitalization of $100,084.00, a P/E ratio of -0.02 and a beta of 1.47. Navidea Biopharmaceuticals has a twelve month low of $0.00 and a twelve month high of $0.15.
About Navidea Biopharmaceuticals
Featured Articles
- Five stocks we like better than Navidea Biopharmaceuticals
- Airline Stocks – Top Airline Stocks to Buy Now
- Emerging Markets: What They Are and Why They Matter
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Recession or Not, These 3 Stocks Are Winners
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.